PT  - JOURNAL ARTICLE
AU  - Langellotto, Fernanda
AU  - Seiler, Benjamin T.
AU  - Yu, Jingyou
AU  - Cartwright, Mark J.
AU  - White, Des
AU  - Yeager, Chyenne
AU  - Super, Michael
AU  - Doherty, Edward J.
AU  - Barouch, Dan H.
AU  - Mooney, David J.
TI  - A rapidly adaptable biomaterial vaccine for SARS-CoV-2
AID  - 10.1101/2020.07.07.192203
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.07.07.192203
4099  - http://biorxiv.org/content/early/2020/07/07/2020.07.07.192203.short
4100  - http://biorxiv.org/content/early/2020/07/07/2020.07.07.192203.full
AB  - The global COVID-19 pandemic motivates accelerated research to develop safe and efficacious vaccines. To address this need, we leveraged a biomaterial vaccine technology that consists of mesoporous silica rods (MSRs) that provide a sustained release of granulocyte-macrophage colony-stimulating factor (GM-CSF) and adjuvants to concentrate and mature antigen-presenting cells at the vaccine site. Here we explored the humoral responses resulting from the use of monophosphoryl lipid A (MPLA) as the adjuvant and SARS-CoV-2 spike proteins S1, S2, the nucleocapsid (N) protein, and receptor binding domain (RBD) as the target antigens. The dose of antigen and impact of pre-manufacturing of vaccines as versus loading antigen just-in-time was explored in these studies. Single shot MSR vaccines induced rapid and robust antibody titers to the presented antigens, even without the use of a boost, and sera from vaccinated animals demonstrated neutralizing activity against a SARS-CoV-2 pseudovirus. Overall, these results suggest the MSR vaccine system may provide potent protective immunity when utilized to present SARS-CoV-2 antigens.Competing Interest StatementThe authors have declared no competing interest.